US4782047A - Aqueous steroid formulations for nasal administration - Google Patents
Aqueous steroid formulations for nasal administration Download PDFInfo
- Publication number
- US4782047A US4782047A US06/866,171 US86617186A US4782047A US 4782047 A US4782047 A US 4782047A US 86617186 A US86617186 A US 86617186A US 4782047 A US4782047 A US 4782047A
- Authority
- US
- United States
- Prior art keywords
- amount
- formulation
- inflammatory steroid
- preservative
- stinging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- This invention relates to aqueous anti-inflammatory steroid formulations suitable for nasal administration, and to methods for treating inflammation of the nasal mucosa by intranasal administration of said formulations.
- Acceptable formulations must be able to dissolve or suspend an active compound without precipitation or undue oxidation of the components. In other words, acceptable formulations must be stable. Acceptable formulations must also avoid creating discomfort upon administration, and will employ only pharmaceutically acceptable components. Finally, acceptable formulations must not support the growth of microorganisms, and so generally include preservatives.
- One aspect of the invention is a stable, preservable, substantially non-stinging aqueous anti-inflammatory steroid formulation suitable for nasal administration, which formulation comprises: an anti-inflammatory steroid in an amount between about 0.01% and about 0.05% (w/v); propylene glycol in an amount between about 2% and about 10% (w/v); PEG 400 in an amount between about 10% and about 25% (w/v); polysorbate 20 in an amount between about 1% and about 4% (w/v); an effective amount of a preservative, preferably between about 0.02% and about 0.08% (w/v); an effective amount of an antioxidant, preferably between about 0.001% and 0.05% (w/v); an effective amount of a stabilizer, preferably between about 0.005% and 0.05%; water; and pH buffering agent sufficient to adjust the pH of the resulting solution to between about 3.5 and about 7.
- Another aspect of the invention is a method of treating inflammation of the nasal mucosa without inducing stinging, which method comprises intranasally administering to a subject in need thereof a substantially non-stinging aqueous anti-inflammatory steroid formulation as described above.
- One aspect of the invention is a stable, preservable, substantially non-stinging aqueous anti-inflammatory steroid formulation suitable for nasal administration, which formulation comprises: an anti-inflammatory steroid in an amount between about 0.01% and about 0.05% (w/v); propylene glycol in an amount between about 2% and about 10% (w/v); PEG 400 in an amount between about 10% and about 25% (w/v); polysorbate 20 in an amount between about 1% and about 4% (w/v); an effective amount of a preservative, preferably between about 0.02% and about 0.08% (w/v); an effective amount of a stabilizer, preferably between about 0.005% and about 0.05%; an effective amount of an antioxidant, preferably between about 0.001% and about 0.05%; water; and a pH buffering agent sufficient to adjust the pH of the resulting solution to between about 3.5 and about 7.
- a preferred subgenus of the invention is the formulation wherein said anti-inflammatory steroid is flunisolide, particularly in an amount of about 0.025% (w/v).
- a preferred class is the formulation wherein said preservative is benzalkonium chloride in an amount between about 0.02% and about 0.08% (w/v); said stabilizer is disodium EDTA in an amount between about 0.005% and about 0.05% (w/v); and said antioxidant is BHT in an amount between about 0.001% and about 0.05% (w/v); especially the formulation which further comprises sorbitol in an amount between about 0.001% and about 5% (w/v).
- a preferred subclass is the formulation wherein said pH buffering agent comprises: citric acid in an amount between about 0.001% and about 0.05% (w/v); and sodium citrate dihydrate in an amount between about 0.001% and about 0.05% (w/v).
- a preferred species is the non-stinging aqueous anti-inflammatory steroid formulation suitable for nasal administration, which formulation comprises:
- propylene glycol in an amount of about 5% (w/v);
- PEG 400 in an amount of about 20% (w/v);
- polysorbate 20 in an amount of about 2.50% (w/v);
- benzalkonium chloride in an amount of about 0.035% (w/v);
- disodium EDTA in an amount of about 0.01% (w/v);
- BHT in an amount of about 0.01% (w/v);
- citric acid in an amount of about 0.005% (w/v);
- sodium citrate dihydrate in an amount of about 0.00765% (w/v);
- Another aspect of the invention is a method of treating inflammation of the nasal mucosa without inducing stinging, which method comprises intranasally administering to a subject in need thereof a substantially non-stinging aqueous anti-inflammatory steroid formulation comprising an anti-inflammatory steroid in an amount between about 0.01% and about 0.05% (w/v); propylene glycol in an amount between about 2% and about 10% (w/v); PEG 400 in an amount between about 10% and about 25% (w/v); polysorbate 20 in an amount between about 1% and about 4% (w/v); an effective amount of a preservative, preferably between about 0.02% and about 0.08% (w/v); an effective amount of a stabilizer, preferably between about 0.005% and about 0.05%; an effective amount of an antioxidant, preferably between about 0.001% and about 0.05%; water; and a pH buffering agent sufficient to adjust the pH of the resulting solution to between about 3.5 and about 7; and water.
- a preferred subgenus is the method wherein said anti-inflammatory steroid is flunisolide in an amount of about 0.025% (w/v), particularly where said preservative is benzalkonium chloride in an amount between about 0.02% and about 0.08% (w/v); said stabilizer is disodium EDTA in an amount between about 0.005% and about 0.05% (w/v); and said antioxidant is BHT in an amount between about 0.001% and about 0.05% (w/v).
- a preferred class is the method which further comprises sorbitol in an amount between about 0.001% and about 5% (w/v).
- a preferred subclass is the method wherein said pH buffering agent comprises citric acid in an amount between about 0.001% and about 0.05% (w/v); and sodium citrate dihydrate in an amount between about 0.001% and about 0.05% (w/v).
- a preferred species of the invention is the method of treating inflammation of the nasal mucosa without inducing stinging, which method comprises intranasally administering to a subject in need thereof a substantially non-stinging aqueous anti-inflammatory steroid formulation comprising
- propylene glycol in an amount of about 5% (w/v);
- PEG 400 in an amount of about 20% (w/v);
- polysorbate 20 in an amount of about 2.50% (w/v);
- benzalkonium chloride in an amount of about 0.035% (w/v);
- disodium EDTA in an amount of about 0.01% (w/v);
- BHT in an amount of about 0.01% (w/v);
- citric acid in an amount of about 0.005% (w/v);
- sodium citrate dihydrate in an amount of about 0.00765% (w/v);
- Polyethylene glycol 400 refers to commercially available mixtures of polymers of the form H--(OCH 2 CH 2 ) n --OH, where the average value of n is between 8.2 and 9.1. Polyethylene glycol 400 is abbreviated herein as "PEG 400.”
- BHA refers to butylated hydroxyanisole, which is a commercially available preservative/antioxidant.
- preservative refers to a compound or mixture of compounds used in a formulation which is useful for reducing or eliminating microbial growth in a formulation.
- a preservative must be pharmaceutically acceptable at the concentrations used, and should not interfere with the action of the active compound in the formulation.
- An "effective amount" of a preservative is that amount necessary to prevent the growth of microorganisms in the formulation. The effective amount may be determined using the USP-BP modified double blind assay.
- Exemplary preservatives include, without limitation, BHA, BHT, thimerosal, potassium sorbate, methylparaben, propylparaben, sodium benzoate and the like.
- Presently preferred preservatives are benzalkonium chloride and thimerosal, particularly benzalkonium chloride.
- antioxidant refers to a compound or mixture of compounds used in a formulation which is useful for preventing the oxidation of active compound(s) in a formulation.
- a antioxidant must be pharmaceutically acceptable at the concentrations used, and should not interfere with the action of the active compound in the formulation.
- An "effective amount" of an antioxidant is that amount necessary to prevent undue oxidation of the active compound under normal storage conditions.
- Presently preferred antioxidants are BHA, and BHT, particularly BHT.
- stabilizer refers to a compound used in a formulation to prevent chemical degradation by means other than oxidation or microbial digestion.
- An "effective amount" of an oxidant is that amount necessary to prevent unacceptable degradation of the active compound.
- the presently preferred stabilizer is disodium EDTA.
- treatment covers any treatment of a disease in a mammal, particularly a human, and includes:
- compositions of the invention are advantageously administered intranasally by means of a "non-propellant" type aerosol or atomizer, especially using a pump-type dispenser.
- a non-propellant type aerosol or atomizer especially using a pump-type dispenser.
- the Calmar Mark II nasal pump Calmar-Albert GmbH
- the Pfeiffer pump Ing.-erich Pfeiffer GmbH & Co. KG
- propylene glycol, PEG 400, and polysorbate 20 are mixed well in an appropriate vessel.
- the desired amount of flunisolide preferably in the form of the hemihydrate
- BHT BHT
- the resulting mixture is heated to 50°-55° C. and mixed until the flunisolide and BHT dissolve.
- the resulting solution is brought to final volume with purified water, filtered through a 3 micron filter, and packaged.
- compositions of the invention are prepared as described in the Preparation above.
- Group 1 received formulations A, B, and D.
- Group 2 received formulations A, C, and E.
- the tests were performed by applying one spray to each nostril, with a rest period of 4 hours between administrations of different formulations.
- compositions C, D, and E The results indicated superior nasal acceptability for compositions C, D, and E.
- each formulation contained 0.025% flunisolide, 2% sorbitol, 0.01% EDTA, and 0.04% benzalkonium chloride.
- Composition 1 corresponds to Composition A of Example 2.
- Compositions 2, 3, 5, and 6 are equivalent to Composition C of Example 2.
- Compositions 4 and 7 are equivalent to Composition D of Example 2.
- compositions 2, 3, 5, and 6 display superior stability as compared to other compositions (1, 4, and 7) in this assay.
- compositions listed below are tested for preservative efficacy using the USP-BP modified double challenge test.
- each composition is prepared with 0.01, 0.02, 0.025, 0.03, 0.035, or 0.04% (w/v) benzalkonium chloride.
- These compositions correspond to compositions A-E of Example 2.
- compositions A-E are prepared, added to culture media, and the resulting test media directly inoculated with challenge organisms. After incubation for 14 days, the test media are inoculated again. The number of colony forming units is recorded over the remaining 14 days of the test.
- compositions A and B were effectively preserved with 0.01% benzalkonium chloride and Composition C was effectively preserved with 0.03% benzalkonium chloride, whereas Composition D required more than 0.04% benzalkonium chloride, and Composition E was not effectively preserved with any concentration of benzalkonium chloride tested.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A non-stinging aqueous anti-inflammatory steroid formulation suitable for intranasal administration comprises: an anti-inflammatory steroid in an amount between about 0.01% and about 0.05% (w/v); propylene glycol in an amount between about 2% and about 10% (w/v); PEG 400 in an amount between about 10% and about 25% (w/v); polysorbate 20 in an amount between about 1% and about 4% (w/v); an effective amount of a preservative; an effective amount of a stabilizer; an effective amount of an antioxidant; water; and pH buffering agent sufficient to adjust the pH of the resulting solution to between about 3.5 and about 7.
Description
1. Field of the Invention
This invention relates to aqueous anti-inflammatory steroid formulations suitable for nasal administration, and to methods for treating inflammation of the nasal mucosa by intranasal administration of said formulations.
2. Related Disclosure
Acceptable formulations must be able to dissolve or suspend an active compound without precipitation or undue oxidation of the components. In other words, acceptable formulations must be stable. Acceptable formulations must also avoid creating discomfort upon administration, and will employ only pharmaceutically acceptable components. Finally, acceptable formulations must not support the growth of microorganisms, and so generally include preservatives.
Anti-inflammatory steroids are difficult to formulate in aqueous solutions due to their generally low solubility in water. Aqueous formulations of anti-inflammatory steroids such as flunisolide suitable for nasal administration are commercially available, for example under the trademark Nasalide®. However, currently available formulations, while safe and effective, are known to cause stinging upon administration in some cases, which is a side effect particularly undesirable when treating nasal inflammation. The novel formulations of the invention are stable, effectively preservable, and are suitable for nasal administration of anti-inflammatory steroids without causing stinging.
One aspect of the invention is a stable, preservable, substantially non-stinging aqueous anti-inflammatory steroid formulation suitable for nasal administration, which formulation comprises: an anti-inflammatory steroid in an amount between about 0.01% and about 0.05% (w/v); propylene glycol in an amount between about 2% and about 10% (w/v); PEG 400 in an amount between about 10% and about 25% (w/v); polysorbate 20 in an amount between about 1% and about 4% (w/v); an effective amount of a preservative, preferably between about 0.02% and about 0.08% (w/v); an effective amount of an antioxidant, preferably between about 0.001% and 0.05% (w/v); an effective amount of a stabilizer, preferably between about 0.005% and 0.05%; water; and pH buffering agent sufficient to adjust the pH of the resulting solution to between about 3.5 and about 7.
Another aspect of the invention is a method of treating inflammation of the nasal mucosa without inducing stinging, which method comprises intranasally administering to a subject in need thereof a substantially non-stinging aqueous anti-inflammatory steroid formulation as described above.
One aspect of the invention is a stable, preservable, substantially non-stinging aqueous anti-inflammatory steroid formulation suitable for nasal administration, which formulation comprises: an anti-inflammatory steroid in an amount between about 0.01% and about 0.05% (w/v); propylene glycol in an amount between about 2% and about 10% (w/v); PEG 400 in an amount between about 10% and about 25% (w/v); polysorbate 20 in an amount between about 1% and about 4% (w/v); an effective amount of a preservative, preferably between about 0.02% and about 0.08% (w/v); an effective amount of a stabilizer, preferably between about 0.005% and about 0.05%; an effective amount of an antioxidant, preferably between about 0.001% and about 0.05%; water; and a pH buffering agent sufficient to adjust the pH of the resulting solution to between about 3.5 and about 7. A preferred subgenus of the invention is the formulation wherein said anti-inflammatory steroid is flunisolide, particularly in an amount of about 0.025% (w/v). A preferred class is the formulation wherein said preservative is benzalkonium chloride in an amount between about 0.02% and about 0.08% (w/v); said stabilizer is disodium EDTA in an amount between about 0.005% and about 0.05% (w/v); and said antioxidant is BHT in an amount between about 0.001% and about 0.05% (w/v); especially the formulation which further comprises sorbitol in an amount between about 0.001% and about 5% (w/v). A preferred subclass is the formulation wherein said pH buffering agent comprises: citric acid in an amount between about 0.001% and about 0.05% (w/v); and sodium citrate dihydrate in an amount between about 0.001% and about 0.05% (w/v). A preferred species is the non-stinging aqueous anti-inflammatory steroid formulation suitable for nasal administration, which formulation comprises:
flunisolide hemihydrate in an amount of about 0.025% (w/v);
propylene glycol in an amount of about 5% (w/v);
PEG 400 in an amount of about 20% (w/v);
polysorbate 20 in an amount of about 2.50% (w/v);
benzalkonium chloride in an amount of about 0.035% (w/v);
disodium EDTA in an amount of about 0.01% (w/v);
BHT in an amount of about 0.01% (w/v);
citric acid in an amount of about 0.005% (w/v);
sodium citrate dihydrate in an amount of about 0.00765% (w/v);
sorbitol in an amount of about 2.00% (w/v); and
water, wherein the pH of the resulting solution is adjusted to about 5.2.
Another aspect of the invention is a method of treating inflammation of the nasal mucosa without inducing stinging, which method comprises intranasally administering to a subject in need thereof a substantially non-stinging aqueous anti-inflammatory steroid formulation comprising an anti-inflammatory steroid in an amount between about 0.01% and about 0.05% (w/v); propylene glycol in an amount between about 2% and about 10% (w/v); PEG 400 in an amount between about 10% and about 25% (w/v); polysorbate 20 in an amount between about 1% and about 4% (w/v); an effective amount of a preservative, preferably between about 0.02% and about 0.08% (w/v); an effective amount of a stabilizer, preferably between about 0.005% and about 0.05%; an effective amount of an antioxidant, preferably between about 0.001% and about 0.05%; water; and a pH buffering agent sufficient to adjust the pH of the resulting solution to between about 3.5 and about 7; and water. A preferred subgenus is the method wherein said anti-inflammatory steroid is flunisolide in an amount of about 0.025% (w/v), particularly where said preservative is benzalkonium chloride in an amount between about 0.02% and about 0.08% (w/v); said stabilizer is disodium EDTA in an amount between about 0.005% and about 0.05% (w/v); and said antioxidant is BHT in an amount between about 0.001% and about 0.05% (w/v). A preferred class is the method which further comprises sorbitol in an amount between about 0.001% and about 5% (w/v). A preferred subclass is the method wherein said pH buffering agent comprises citric acid in an amount between about 0.001% and about 0.05% (w/v); and sodium citrate dihydrate in an amount between about 0.001% and about 0.05% (w/v). A preferred species of the invention is the method of treating inflammation of the nasal mucosa without inducing stinging, which method comprises intranasally administering to a subject in need thereof a substantially non-stinging aqueous anti-inflammatory steroid formulation comprising
flunisolide hemihydrate in an amount of about 0.025% (w/v);
propylene glycol in an amount of about 5% (w/v);
PEG 400 in an amount of about 20% (w/v);
polysorbate 20 in an amount of about 2.50% (w/v);
benzalkonium chloride in an amount of about 0.035% (w/v);
disodium EDTA in an amount of about 0.01% (w/v);
BHT in an amount of about 0.01% (w/v);
citric acid in an amount of about 0.005% (w/v);
sodium citrate dihydrate in an amount of about 0.00765% (w/v);
sorbitol in an amount of about 2.00% (w/v); and
water, wherein the pH of the resulting solution is adjusted to about 5.2.
As used herein, the term "anti-inflammatory steroid" refers to a steroid compound which is pharmaceutically acceptable, and which is known to be useful in reducing inflammation. Particularly suitable anti-inflammatory steroids are flunisolide and beclomethasone. Flunisolide is most advantageously used in the form of the hemihydrate, as that form is non-hygroscopic and is thus easiest to handle curing formulation. Flunisolide is commercially available, and can be prepared as described in U.S. Pat. No. 4,273,710, incorporated herein by reference. Beclomethasone is also commercially available, and can be prepared as described in G.B. Pat. No. 912,378.
Propylene glycol refers to 1,2-propanediol. Propylene glycol is available commercially.
Polyethylene glycol 400 refers to commercially available mixtures of polymers of the form H--(OCH2 CH2)n --OH, where the average value of n is between 8.2 and 9.1. Polyethylene glycol 400 is abbreviated herein as "PEG 400."
Polysorbate 20 refers to commercially available polyoxyethylene-sorbitan monoesters, for example Tween® 20.
The term "BHT" refers to butylated hydroxytoluene, which is a commercially available preservative/antioxidant.
The term "BHA" refers to butylated hydroxyanisole, which is a commercially available preservative/antioxidant.
The term "preservative" refers to a compound or mixture of compounds used in a formulation which is useful for reducing or eliminating microbial growth in a formulation. A preservative must be pharmaceutically acceptable at the concentrations used, and should not interfere with the action of the active compound in the formulation. An "effective amount" of a preservative is that amount necessary to prevent the growth of microorganisms in the formulation. The effective amount may be determined using the USP-BP modified double blind assay. Exemplary preservatives include, without limitation, BHA, BHT, thimerosal, potassium sorbate, methylparaben, propylparaben, sodium benzoate and the like. Presently preferred preservatives are benzalkonium chloride and thimerosal, particularly benzalkonium chloride.
The term "antioxidant" refers to a compound or mixture of compounds used in a formulation which is useful for preventing the oxidation of active compound(s) in a formulation. A antioxidant must be pharmaceutically acceptable at the concentrations used, and should not interfere with the action of the active compound in the formulation. An "effective amount" of an antioxidant is that amount necessary to prevent undue oxidation of the active compound under normal storage conditions. Presently preferred antioxidants are BHA, and BHT, particularly BHT.
The term "stabilizer" refers to a compound used in a formulation to prevent chemical degradation by means other than oxidation or microbial digestion. An "effective amount" of an oxidant is that amount necessary to prevent unacceptable degradation of the active compound. The presently preferred stabilizer is disodium EDTA.
The term "treatment" as used herein covers any treatment of a disease in a mammal, particularly a human, and includes:
(i) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it;
(ii) inhibiting the disease, i.e., arresting its development; or
(iii) relieving the disease, i.e., causing regression of the disease.
The compositions of the invention are advantageously administered intranasally by means of a "non-propellant" type aerosol or atomizer, especially using a pump-type dispenser. For example, the Calmar Mark II nasal pump (Calmar-Albert GmbH) and the Pfeiffer pump (Ing.-erich Pfeiffer GmbH & Co. KG) are generally useful.
Preferably, the aerosol pump will deliver a spray in which less than 1% of the droplets are below 16 μm in diameter. This minimizes the amount of composition which reaches the lungs.
Compositions of the invention may be prepared as follows:
The desired amounts of propylene glycol, PEG 400, and polysorbate 20 are mixed well in an appropriate vessel. To this mixture is added the desired amount of flunisolide (preferably in the form of the hemihydrate), and BHT. The resulting mixture is heated to 50°-55° C. and mixed until the flunisolide and BHT dissolve.
The desired amount of sorbitol (e.g., as a 70% solution) is mixed with citric acid and sodium citrate (in the proper proportions for obtaining the desired buffer), benzalkonium chloride (e.g. as a 50% solution), edetate disodium, and water, to form a solution which is approximately 90% water. This solution is then mixed with the flunisolide solution and the pH measured and adjusted with HCl solution or NaOH solution as appropriate.
The resulting solution is brought to final volume with purified water, filtered through a 3 micron filter, and packaged.
The following are representative compositions of the invention. The compositions are prepared as described in the Preparation above.
______________________________________
Compound amount % (w/v)
______________________________________
(A)
flunisolide hemihydrate
0.025
propylene glycol 5.0
PEG 400 20.0
polysorbate 20 2.50
benzalkonium chloride
0.035
disodium EDTA 0.01
BHT 0.01
citric acid 0.005
sodium citrate.2H.sub.2 O
0.00765
sorbitol 2.00
water qs 100.0
pH 5.2
(B)
flunisolide hemihydrate
0.01
propylene glycol 2.0
PEG 400 10.0
polysorbate 20 1.0
benzalkonium chloride
0.03
disodium EDTA 0.01
BHT 0.01
citric acid 0.005
sodium citrate.2H.sub.2 O
0.00765
sorbitol 2.00
water qs 100.0
pH 5.3
(C)
beclomethasone 0.05
propylene glycol 10.0
PEG 400 25.0
polysorbate 20 4.0
benzalkonium chloride
0.03
disodium EDTA 0.01
BHT 0.01
citric acid 0.005
sodium citrate.2H.sub.2 O
0.00765
sorbitol 5.00
water qs 100.0
pH 5.2
______________________________________
The following example illustrates a procedure for assaying the nasal acceptability of various compositions.
Eighteen volunteers were randomly divided into two groups. Group 1 received formulations A, B, and D. Group 2 received formulations A, C, and E. The tests were performed by applying one spray to each nostril, with a rest period of 4 hours between administrations of different formulations.
The following parameters were recorded, both immediately and 15 minutes after administration: nasal stinging, taste, other sensations, and willingness to use the spray three times daily. The formulations tested were as follows:
______________________________________
amount % (w/v)
Compound
A B C D E
______________________________________
propylene
20.0 7.0 5.0 0.0 0.0
glycol
PEG 3350
15.0 0.0 0.0 0.0 0.0
PEG 400 0.0 40.0 20.0 15.0 0.0
polysor-
0.0 0.0 2.50 3.5 3.5
bate 20
benzalkon-
0.02 0.02 0.02 0.02 0.02
ium Cl
disodium
0.01 0.01 0.01 0.01 0.01
EDTA
BHA 0.002 0.002 0.002 0.002 0.002
citric acid
0.005 0.005 0.005 0.005 0.005
Na citrate
0.0077 0.0077 0.0077 0.0077 0.0077
sorbitol
0.0 3.0 2.0 2.0 2.0
water qs
100.0 100.0 100.0 100.0 100.0
pH 5.3 5.3 5.3 5.3 5.3
______________________________________
The results indicated superior nasal acceptability for compositions C, D, and E.
The stability of formulations was investigated as follows:
Six formulations were prepared as set out below for testing. Ten mL of each formulation was filled and sealed in amber glass ampoules and stored at 80° C. (1/2 month), 60° C. (1.5 months), and 15° C. for the period of time stated. In addition, 25 mL of each solution was filled in 1 oz round high density polyethylene bottles and screw capped. These bottles were stored at 50° C. (2, 3, 8, and 10 months), 40° C. (8 and 10 months), and room temperature (RT) (8 and 10 months). At the end of the appropriate time period, the steroid content was determined using HPLC, and the pH of the solution measured. The results are normalized against the 15° C. data for the appropriate time periods.
______________________________________ amount % (w/v) Composition 1 2 3 4 5 6 7 ______________________________________ PG 20.0 5.0 5.0 0.0 5.0 5.0 0.0 PEG 15.0 0.0 0.0 0.0 0.0 0.0 0.0 3350 PEG 0.0 20.0 20.0 15.0 20.0 20.0 15.0 400 PS 0.0 2.5 2.5 3.5 2.5 2.5 3.5 20 BHA 0.01 0.01 0.01 0.01 0.0 0.0 0.0 BHT 0.0 0.0 0.0 0.0 0.01 0.01 0.01 cit- 0.01 0.01 0.02 0.01 0.02 0.01 0.02 rate wa- 100.0 100.0 100.0 100.0 100.0 100.0 100.0 ter qs ______________________________________
In addition, each formulation contained 0.025% flunisolide, 2% sorbitol, 0.01% EDTA, and 0.04% benzalkonium chloride. Composition 1 corresponds to Composition A of Example 2. Compositions 2, 3, 5, and 6 are equivalent to Composition C of Example 2. Compositions 4 and 7 are equivalent to Composition D of Example 2.
The results indicated that the formulations of the invention (Compositions 2, 3, 5, and 6) display superior stability as compared to other compositions (1, 4, and 7) in this assay.
The compositions listed below are tested for preservative efficacy using the USP-BP modified double challenge test.
______________________________________
amount % (w/v)
Composition
A B C D E
______________________________________
flunisolide
0.025 0.025 0.025 0.025 0.025
propylene glycol
20.0 7.0 5.0 0.0 0.0
PEG 3350 15.0 0.0 0.0 0.0 0.0
PEG 400 0.0 40.0 20.0 15.0 0.0
polysorbate 20
0.0 0.0 2.50 3.5 3.5
disodium EDTA
0.01 0.01 0.01 0.01 0.01
BHA 0.002 0.002 0.002 0.002 0.002
citrate buffer
0.01 0.01 0.01 0.01 0.01
sorbitol 0.0 3.0 2.0 2.0 2.0
water qs 100.0 100.0 100.0 100.0 100.0
pH 5.3 5.3 5.3 5.3 5.3
______________________________________
In addition, each composition is prepared with 0.01, 0.02, 0.025, 0.03, 0.035, or 0.04% (w/v) benzalkonium chloride. These compositions correspond to compositions A-E of Example 2.
Compositions A-E are prepared, added to culture media, and the resulting test media directly inoculated with challenge organisms. After incubation for 14 days, the test media are inoculated again. The number of colony forming units is recorded over the remaining 14 days of the test.
The results indicated that Compositions A and B were effectively preserved with 0.01% benzalkonium chloride and Composition C was effectively preserved with 0.03% benzalkonium chloride, whereas Composition D required more than 0.04% benzalkonium chloride, and Composition E was not effectively preserved with any concentration of benzalkonium chloride tested.
Claims (15)
1. A stable, effectively preservable, substantially non-stinging aqueous anti-inflammatory steroid formulation suitable for intranasal administration, which formulation comprises:
an anti-inflammatory steroid in an amount between about 0.01% and about 0.05% (w/v);
propylene glycol in an amount between about 2% and about 10% (w/v);
PEG 400 in an amount between about 10% and about 25% (w/v);
polysorbate 20 in an amount between about 1% and about 4% (w/v);
an effective amount of preservative;
an effective amount of antioxidant;
an effective amount of stabilizer;
water; and
pH buffering agent sufficient to adjust the pH of the resulting solution to between about 3.5 and about 7.
2. The formulation of claim 1 which comprises:
______________________________________
Flunisolide (hemihydrate)
0.0255% (w/v)
Propylene Glycol 5.0% (w/v)
PEG 400 20.0% (w/v)
Polysorbate 20 2.50% (w/v)
Benzalkonium Chloride (50%)
0.07% (w/v)
Edetate Disodium 0.01% (w/v)
Butylated Hydroxyanisole
0.01% (w/v)
Butylated Hydroxytoluene
0.01% (w/v)
Citric Acid (Anhydrous)
0.005% (w/v)
Trisodium Citrate Dihydrate
0.00765% (w/v)
Sorbitol (70%) 2.86% (w/v)
Purified Water, q.s. to
100.0 and
adjust pH to 5.3.
______________________________________
3. The formulation of claim 1 which comprises:
preservative in an amount between about 0.02% and about 0.08% (w/v);
antioxidant in an amount between about 0.001% and about 0.05% (w/v); and
stabilizer in an amount between about 0.005% and about 0.05% (w/v).
4. The formulation of claim 3 wherein said anti-inflammatory steroid is flunisolide in an amount of about 0.025% (w/v).
5. The formulation of claim 4 wherein:
said preservative is benzalkonium chloride;
said stabilizer is disodium EDTA; and
said antioxidant is BHT.
6. The formulation of claim 5 which further comprises sorbitol in an amount between about 0.001% and about 5% (w/v).
7. The formulation of claim 6 wherein said pH buffering agent comprises:
citric acid in an amount between about 0.001% and about 0.05% (w/v); and
sodium citrate dihydrate in an amount between about 0.001% and about 0.05% (w/v).
8. A stable, effectively preservable, substantially non-stinging aqueous anti-inflammatory steroid formulation suitable for intranasal administration, which formulation comprises:
flunisolide hemihydrate in an amount of about 0.025% (w/v);
propylene glycol in an amount of about 5% (w/v);
PEG 400 in an amount of about 20% (w/v);
polysorbate 20 in an amount of about 2.50% (w/v);
benzalkonium chloride in an amount of about 0.035% (w/v);
disodium EDTA in an amount of about 0.01% (w/v);
BHT in an amount of about 0.01% (w/v);
citric acid in an amount of about 0.005% (w/v);
sodium citrate dihydrate in an amount of about 0.00765% (w/v);
sorbitol in an amount of about 2.00% (w/v); and
water, wherein the pH of the resulting solution is adjusted to about 5.2.
9. A method of treating inflammation of the nasal mucosa without inducing stinging, which method comprises intranasally administering to a subject in need thereof a substantially non-stinging aqueous anti-inflammatory steroid formulation comprising
an anti-inflammatory steroid in an amount between about 0.01% and about 0.05% (w/v);
propylene glycol in an amount between about 2% and about 10% (w/v);
PEG 400 in an amount between about 10% and about 25% (w/v);
polysorbate 20 in an amount between about 1% and about 4% (w/v);
an effective amount of preservative;
an effective amount of antioxidant;
an effective amount of stabilizer;
water; and
pH buffering agent sufficient to adjust the pH of the resulting solution to between about 3.5 and about 7.
10. The method of claim 9 wherein said formulation comprises:
preservative in an amount between about 0.02% and about 0.08% (w/v);
antioxidant in an amount between about 0.001% and about 0.05% (w/v); and
stabilizer in an amount between about 0.005% and about 0.05% (w/v).
11. The method of claim 10 wherein said anti-inflammatory steroid is flunisolide in an amount of about 0.025% (w/v).
12. The method of claim 11 wherein:
said preservative comprises benzalkonium chloride;
said stabilizer comprises disodium EDTA; and
said antioxidant comprises BHT.
13. The method of claim 12 which further comprises sorbitol in an amount between about 0.001% and about 5% (w/v).
14. The method of claim 13 wherein said pH buffering agent comprises:
citric acid in an amount between about 0.001% and about 0.05% (w/v); and
sodium citrate dihydrate in an amount between about 0.001% and about 0.05% (w/v).
15. A method of treating inflammation of the nasal mucosa without inducing stinging, which method comprises intranasally administering to a subject in need thereof a substantially non-stinging aqueous anti-inflammatory steroid formulation comprising
flunisolide hemihydrate in an amount of about 0.025% (w/v);
propylene glycol in an amount of about 5% (w/v);
PEG 400 in an amount of about 20% (w/v);
polysorbate 20 in an amount of about 2.50% (w/v);
benzalkonium chloride in an amount of about 0.035% (w/v);
disodium EDTA in an amount of about 0.01% (w/v);
BHT in an amount of about 0.01% (w/v);
citric acid in an amount of about 0.005% (w/v);
sodium citrate dihydrate in an amount of about 0.00765% (w/v);
sorbitol in an amount of about 2.00% (w/v); and
water, wherein the pH of the resulting solution is adjusted to about 5.2.
Priority Applications (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/866,171 US4782047A (en) | 1986-05-22 | 1986-05-22 | Aqueous steroid formulations for nasal administration |
| AU73273/87A AU609718B2 (en) | 1986-05-22 | 1987-05-21 | Aqueous steroid formulations for nasal administration |
| IL82615A IL82615A (en) | 1986-05-22 | 1987-05-21 | Aqueous steroid formulations for nasal administration |
| KR1019870005032A KR950008308B1 (en) | 1986-05-22 | 1987-05-21 | Aqueous steroid preparations for intranasal administration |
| CA000537690A CA1288048C (en) | 1986-05-22 | 1987-05-21 | Aqueous steroid formulations for nasal administration |
| EP87107416A EP0246652B1 (en) | 1986-05-22 | 1987-05-21 | Aqueous steroid formulations for nasal administration |
| DE8787107416T DE3771389D1 (en) | 1986-05-22 | 1987-05-21 | AQUEOUS STEROID FORMULATIONS FOR NASAL ADMINISTRATION. |
| AT87107416T ATE65183T1 (en) | 1986-05-22 | 1987-05-21 | AQUEOUS STEROID FORMULATIONS FOR NASAL ADMINISTRATION. |
| ES198787107416T ES2031467T3 (en) | 1986-05-22 | 1987-05-21 | AQUEOUS FORMULATIONS OF STEROIDS SUITABLE FOR ADMINISTRATION VIA NASAL. |
| ZA873663A ZA873663B (en) | 1986-05-22 | 1987-05-21 | Aqueous steroid formulations for nasal administration |
| FI872231A FI88459C (en) | 1986-05-22 | 1987-05-21 | Process for the preparation of a steroid composition suitable for intranasal application |
| IE133587A IE60259B1 (en) | 1986-05-22 | 1987-05-21 | "Aqueous steroid formulations for nasal administration" |
| DK198702586A DK175238B1 (en) | 1986-05-22 | 1987-05-21 | Aqueous steroid formulations, method of preparation thereof, and use of such steroid formulations for the manufacture of a medicament for treating the nasal mucosa |
| NZ220394A NZ220394A (en) | 1986-05-22 | 1987-05-21 | Aqueous steroid formulation adapted for intranasal application and having an anti-inflammatory effect |
| IT20621/87A IT1205667B (en) | 1986-05-22 | 1987-05-21 | STEROID FORMULATIONS IN AQUEOUS SOLUTION FOR NASAL ADMINISTRATION |
| NO872127A NO173365C (en) | 1986-05-22 | 1987-05-21 | Process for the preparation of a substantially non-starchy aqueous anti-inflammatory steroid preparation suitable for intranasal administration |
| JP62126846A JP2521291B2 (en) | 1986-05-22 | 1987-05-21 | Aqueous steroid preparation for nasal administration |
| US07/247,008 US4983595A (en) | 1986-05-22 | 1988-09-20 | Aqueous steroid formulations for nasal administration |
| GR91400394T GR3002317T3 (en) | 1986-05-22 | 1991-07-18 | Aqueous steroid formulations for nasal administration |
| HK39094A HK39094A (en) | 1986-05-22 | 1994-04-21 | Aqueous steroid formulations for nasal administration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/866,171 US4782047A (en) | 1986-05-22 | 1986-05-22 | Aqueous steroid formulations for nasal administration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/247,008 Continuation US4983595A (en) | 1986-05-22 | 1988-09-20 | Aqueous steroid formulations for nasal administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4782047A true US4782047A (en) | 1988-11-01 |
Family
ID=25347059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/866,171 Expired - Lifetime US4782047A (en) | 1986-05-22 | 1986-05-22 | Aqueous steroid formulations for nasal administration |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4782047A (en) |
| EP (1) | EP0246652B1 (en) |
| JP (1) | JP2521291B2 (en) |
| KR (1) | KR950008308B1 (en) |
| AT (1) | ATE65183T1 (en) |
| AU (1) | AU609718B2 (en) |
| CA (1) | CA1288048C (en) |
| DE (1) | DE3771389D1 (en) |
| DK (1) | DK175238B1 (en) |
| ES (1) | ES2031467T3 (en) |
| FI (1) | FI88459C (en) |
| GR (1) | GR3002317T3 (en) |
| HK (1) | HK39094A (en) |
| IE (1) | IE60259B1 (en) |
| IL (1) | IL82615A (en) |
| IT (1) | IT1205667B (en) |
| NO (1) | NO173365C (en) |
| NZ (1) | NZ220394A (en) |
| ZA (1) | ZA873663B (en) |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4983595A (en) * | 1986-05-22 | 1991-01-08 | Syntex (U.S.A.) Inc. | Aqueous steroid formulations for nasal administration |
| WO1997035627A1 (en) * | 1996-03-26 | 1997-10-02 | Virotex Corporation | Method and composition for cleansing wounds with minimal cytotoxicity for minimal scarring |
| US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| WO2000000181A1 (en) * | 1998-06-26 | 2000-01-06 | Lds Technologies, Inc. | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US20030206867A1 (en) * | 2000-05-10 | 2003-11-06 | Wermeling Daniel P. | System and method for intranasal administration of lorazepam |
| US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
| US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
| US20050153946A1 (en) * | 2003-12-24 | 2005-07-14 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
| US6948492B2 (en) | 2000-08-15 | 2005-09-27 | University Of Kentucky Research Foundation | Programmable multi-dose intranasal drug delivery device |
| US20060045850A1 (en) * | 2004-08-30 | 2006-03-02 | Qpharma, Llc | Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids |
| US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
| KR100767976B1 (en) | 2006-08-25 | 2007-10-18 | 한국유나이티드제약 주식회사 | Pharmaceutical compositions effective against nasal dryness |
| US20090227568A1 (en) * | 2007-01-19 | 2009-09-10 | Sveinbjorn Gizurarson | Methods and compositions for the delivery of a therapeutic agent |
| US7700588B2 (en) | 2004-01-14 | 2010-04-20 | Merkus Franciscus Wilhelmus He | Pharmaceutical compositions comprising midazolam in a high concentration |
| US20100210580A1 (en) * | 2005-08-17 | 2010-08-19 | Fleming And Company, Pharmaceuticals | Vitamin B12 Nasal Spray and Method of Use |
| US8466134B1 (en) | 1998-06-26 | 2013-06-18 | Athena Neurosciences, Inc. | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US8940714B2 (en) | 2003-03-04 | 2015-01-27 | Par Pharmaceutical, Inc. | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
| US9901585B2 (en) | 2002-06-14 | 2018-02-27 | Cipla Limited | Combination of azelastine and fluticasone for nasal administration |
| US9919050B2 (en) | 2004-11-24 | 2018-03-20 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine |
| US11975096B2 (en) | 2014-07-08 | 2024-05-07 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0311016A (en) * | 1989-06-09 | 1991-01-18 | Tokyo Tanabe Co Ltd | Aqueous preparation of pyrido(1,2-a)pyrimidine derivative |
| GB9103824D0 (en) * | 1991-02-23 | 1991-04-10 | Fisons Ag | Formulation |
| US5338732A (en) * | 1991-06-18 | 1994-08-16 | Bristol-Myers Squibb Company | Megestrol acetate formulation |
| AU681452B2 (en) * | 1993-10-21 | 1997-08-28 | Hisamitsu Pharmaceutical Co., Inc. | Pernasal composition and pernasal preparation containing thesame |
| GB9918559D0 (en) * | 1999-08-07 | 1999-10-06 | Glaxo Wellcome Kk | Novel pharmaceutical formulation |
| CA2493764C (en) | 2002-08-01 | 2011-05-24 | Aesgen, Inc. | Improved treatment of cancer with glutamine |
| US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
| JP5238779B2 (en) * | 2003-04-25 | 2013-07-17 | ロート製薬株式会社 | Nasal drops |
| JP4632687B2 (en) * | 2003-04-25 | 2011-02-16 | ロート製薬株式会社 | Nasal drops |
| CN101678112B (en) | 2007-01-19 | 2016-08-31 | 哈南亚有限公司 | For delivering the method and composition of therapeutic agent |
| JP2011001317A (en) * | 2009-06-19 | 2011-01-06 | Fumakilla Ltd | Cleaning agent for nose |
| CA2905587A1 (en) | 2013-03-15 | 2014-09-18 | Medicis Pharmaceutical Corporation | Topical compositions of flunisolide and methods of treatment |
| JP6097787B2 (en) * | 2015-06-09 | 2017-03-15 | パル ファーマシューティカル， インコーポレーテッド | Cyanocobalamin low viscosity aqueous formulation for intranasal delivery |
| EA036233B1 (en) | 2015-07-16 | 2020-10-16 | Мариномед Биотек Аг | Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs |
| US11510859B2 (en) | 2015-07-16 | 2022-11-29 | Marinomed Biotech Ag | Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444762A (en) * | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2989437A (en) * | 1955-06-08 | 1961-06-20 | Upjohn Co | Anti-inflammatory and anti-bacterial decongestant nasal spray compositions |
| MX3864E (en) * | 1975-05-27 | 1981-08-26 | Syntex Corp | A PROCESS TO PREPARE THE CRYSTALLINE COMPOUND 6-FLUIRO-11B 21-DIHIROXI-16 17-ISOPROPILIDENDIOXIPREGNA-1 4-DIEN-3 20-DIONA |
| DE2750090A1 (en) * | 1976-11-19 | 1978-06-01 | Sandoz Ag | NEW FORMS OF ADMINISTRATION FOR ORGANIC COMPOUNDS |
| US4344940A (en) * | 1981-11-30 | 1982-08-17 | E. R. Squibb & Sons, Inc. | Steroid formulation containing dipotassium EDTA |
| US4603131A (en) * | 1982-04-26 | 1986-07-29 | Bernstein Joel E | Method and composition for treating and preventing irritation of the mucous membranes of the nose |
-
1986
- 1986-05-22 US US06/866,171 patent/US4782047A/en not_active Expired - Lifetime
-
1987
- 1987-05-21 JP JP62126846A patent/JP2521291B2/en not_active Expired - Lifetime
- 1987-05-21 ES ES198787107416T patent/ES2031467T3/en not_active Expired - Lifetime
- 1987-05-21 KR KR1019870005032A patent/KR950008308B1/en not_active IP Right Cessation
- 1987-05-21 AU AU73273/87A patent/AU609718B2/en not_active Ceased
- 1987-05-21 NO NO872127A patent/NO173365C/en unknown
- 1987-05-21 ZA ZA873663A patent/ZA873663B/en unknown
- 1987-05-21 AT AT87107416T patent/ATE65183T1/en not_active IP Right Cessation
- 1987-05-21 EP EP87107416A patent/EP0246652B1/en not_active Expired - Lifetime
- 1987-05-21 IL IL82615A patent/IL82615A/en not_active IP Right Cessation
- 1987-05-21 IT IT20621/87A patent/IT1205667B/en active
- 1987-05-21 NZ NZ220394A patent/NZ220394A/en unknown
- 1987-05-21 IE IE133587A patent/IE60259B1/en not_active IP Right Cessation
- 1987-05-21 DE DE8787107416T patent/DE3771389D1/en not_active Expired - Lifetime
- 1987-05-21 FI FI872231A patent/FI88459C/en not_active IP Right Cessation
- 1987-05-21 CA CA000537690A patent/CA1288048C/en not_active Expired - Lifetime
- 1987-05-21 DK DK198702586A patent/DK175238B1/en active
-
1991
- 1991-07-18 GR GR91400394T patent/GR3002317T3/en unknown
-
1994
- 1994-04-21 HK HK39094A patent/HK39094A/en not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444762A (en) * | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
Non-Patent Citations (2)
| Title |
|---|
| Physician s Desk Reference, 38th ed. (1984), p. 1981; Nasalide . * |
| Physician's Desk Reference, 38th ed. (1984), p. 1981; Nasalide®. |
Cited By (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4983595A (en) * | 1986-05-22 | 1991-01-08 | Syntex (U.S.A.) Inc. | Aqueous steroid formulations for nasal administration |
| US5762917A (en) * | 1994-09-27 | 1998-06-09 | Virotex Corporation | Method and composition for cleansing wounds with minimal cytotoxicity for minimal scarring |
| WO1997035627A1 (en) * | 1996-03-26 | 1997-10-02 | Virotex Corporation | Method and composition for cleansing wounds with minimal cytotoxicity for minimal scarring |
| US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| US6143329A (en) * | 1996-07-03 | 2000-11-07 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| US20070031887A1 (en) * | 1996-07-03 | 2007-02-08 | Soo-Il Kim | Aqueous-based pharmaceutical composition |
| US7977045B2 (en) | 1996-07-03 | 2011-07-12 | Aventis Pharmaceuticals Inc. | Aqueous-based pharmaceutical composition |
| US20100222314A1 (en) * | 1996-07-03 | 2010-09-02 | Soo-Il Kim | Aqueous-based Pharmaceutical Composition |
| WO2000000181A1 (en) * | 1998-06-26 | 2000-01-06 | Lds Technologies, Inc. | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US8466134B1 (en) | 1998-06-26 | 2013-06-18 | Athena Neurosciences, Inc. | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US8198291B2 (en) | 2000-05-10 | 2012-06-12 | University Of Kentucky Research Foundation | Intranasal opioid compositions |
| US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
| US20110118294A1 (en) * | 2000-05-10 | 2011-05-19 | Wermeling Daniel P | Intranasal Opioid Compositions |
| US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
| US20060147386A1 (en) * | 2000-05-10 | 2006-07-06 | Wermeling Daniel P | System and method for intranasal administration of lorazepam |
| US20030206867A1 (en) * | 2000-05-10 | 2003-11-06 | Wermeling Daniel P. | System and method for intranasal administration of lorazepam |
| US20110023870A1 (en) * | 2000-05-10 | 2011-02-03 | Wermeling Daniel P | Intranasal Opioid Compositions, Delivery Devices and Methods of Using Same |
| US20070209660A1 (en) * | 2000-05-10 | 2007-09-13 | Wermeling Daniel P | Intranasal Opioid Compositions, Delivery Devices and Methods of Using Same |
| US20100331354A1 (en) * | 2000-05-10 | 2010-12-30 | Wermeling Daniel P | Intranasal Opioid Compositions |
| US20080004305A1 (en) * | 2000-05-10 | 2008-01-03 | Wermeling Daniel P | Intranasal Opioid Compositions |
| US6948492B2 (en) | 2000-08-15 | 2005-09-27 | University Of Kentucky Research Foundation | Programmable multi-dose intranasal drug delivery device |
| US20060021614A1 (en) * | 2000-08-15 | 2006-02-02 | Wermeling Daniel P | Programmable multi-dose intranasal drug delivery service |
| US7559321B2 (en) | 2000-08-15 | 2009-07-14 | University Of Kentucky Research Foundation | Programmable multi-dose intranasal drug delivery device |
| US20070071687A1 (en) * | 2001-02-20 | 2007-03-29 | Wermeling Daniel P | Intranasal benzodiazepine compositions |
| US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
| US20100113426A1 (en) * | 2001-02-20 | 2010-05-06 | Wermeling Daniel P | Intranasal Benzodiazepine Compositions |
| US9901585B2 (en) | 2002-06-14 | 2018-02-27 | Cipla Limited | Combination of azelastine and fluticasone for nasal administration |
| US8940714B2 (en) | 2003-03-04 | 2015-01-27 | Par Pharmaceutical, Inc. | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
| US9415007B2 (en) | 2003-03-04 | 2016-08-16 | Par Pharmaceutical, Inc. | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
| US20050153946A1 (en) * | 2003-12-24 | 2005-07-14 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
| US7700588B2 (en) | 2004-01-14 | 2010-04-20 | Merkus Franciscus Wilhelmus He | Pharmaceutical compositions comprising midazolam in a high concentration |
| US20060045850A1 (en) * | 2004-08-30 | 2006-03-02 | Qpharma, Llc | Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids |
| US9919050B2 (en) | 2004-11-24 | 2018-03-20 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine |
| US20100210580A1 (en) * | 2005-08-17 | 2010-08-19 | Fleming And Company, Pharmaceuticals | Vitamin B12 Nasal Spray and Method of Use |
| US10251908B2 (en) | 2005-08-17 | 2019-04-09 | Endo Pharmaceuticals Inc. | Vitamin B12 nasal spray and method of use |
| US9186374B2 (en) | 2005-08-17 | 2015-11-17 | Par Pharmaceutical, Inc. | Vitamin B12 nasal spray and method of use |
| US10052344B2 (en) | 2005-08-17 | 2018-08-21 | Endo Pharmaceuticals Inc. | Vitamin B12 nasal spray and method of use |
| KR100767976B1 (en) | 2006-08-25 | 2007-10-18 | 한국유나이티드제약 주식회사 | Pharmaceutical compositions effective against nasal dryness |
| US8217033B2 (en) | 2007-01-19 | 2012-07-10 | Hananja Ehf | Methods and compositions for the delivery of a therapeutic agent |
| US20090227568A1 (en) * | 2007-01-19 | 2009-09-10 | Sveinbjorn Gizurarson | Methods and compositions for the delivery of a therapeutic agent |
| US9687495B2 (en) | 2007-01-19 | 2017-06-27 | Hananja Ehf | Methods and systems for the delivery of a therapeutic agent |
| US9289432B2 (en) | 2007-01-19 | 2016-03-22 | HANANJA EHF and UNIVERSITY OF ICELAND | Methods and compositions for the delivery of a therapeutic agent |
| US10052333B2 (en) | 2007-01-19 | 2018-08-21 | University Of Iceland | Methods and systems for the delivery of a therapeutic agent |
| US8809322B2 (en) | 2007-01-19 | 2014-08-19 | Hananja Ehf | Methods and compositions for the delivery of a therapeutic agent |
| US11975096B2 (en) | 2014-07-08 | 2024-05-07 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1205667B (en) | 1989-03-31 |
| DK258687A (en) | 1987-11-23 |
| CA1288048C (en) | 1991-08-27 |
| IT8720621A0 (en) | 1987-05-21 |
| GR3002317T3 (en) | 1992-12-30 |
| AU7327387A (en) | 1987-11-26 |
| JP2521291B2 (en) | 1996-08-07 |
| ZA873663B (en) | 1988-12-28 |
| FI88459C (en) | 1993-05-25 |
| EP0246652A2 (en) | 1987-11-25 |
| KR870010862A (en) | 1987-12-18 |
| KR950008308B1 (en) | 1995-07-27 |
| IL82615A0 (en) | 1987-11-30 |
| NZ220394A (en) | 1990-04-26 |
| NO173365C (en) | 1993-12-08 |
| DK175238B1 (en) | 2004-07-19 |
| FI872231A0 (en) | 1987-05-21 |
| NO872127D0 (en) | 1987-05-21 |
| JPS62283927A (en) | 1987-12-09 |
| EP0246652B1 (en) | 1991-07-17 |
| DE3771389D1 (en) | 1991-08-22 |
| NO173365B (en) | 1993-08-30 |
| NO872127L (en) | 1987-11-23 |
| AU609718B2 (en) | 1991-05-09 |
| IE60259B1 (en) | 1994-06-29 |
| IL82615A (en) | 1991-11-21 |
| DK258687D0 (en) | 1987-05-21 |
| FI872231L (en) | 1987-11-23 |
| EP0246652A3 (en) | 1988-02-03 |
| ES2031467T3 (en) | 1992-12-16 |
| HK39094A (en) | 1994-04-29 |
| FI88459B (en) | 1993-02-15 |
| ATE65183T1 (en) | 1991-08-15 |
| IE871335L (en) | 1987-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4782047A (en) | Aqueous steroid formulations for nasal administration | |
| US4983595A (en) | Aqueous steroid formulations for nasal administration | |
| US6150418A (en) | Active substance concentrate with formoterol, suitable for storage | |
| JP2515788B2 (en) | Remedies for eye inflammation | |
| DE60034476T2 (en) | TOPICAL NOSE TREATMENT WITH DESLORATADIN AND MOMETASON FUROAT | |
| US6514520B2 (en) | Stabilized antihistamine syrup | |
| CA2343123C (en) | Active substance concentrate with formoterol, suitable for storage | |
| US8450339B2 (en) | Compositions for treatment of common cold | |
| US3975519A (en) | Method for increasing the oxygen partial pressure in the bloodstream of mammals | |
| BRPI0713933A2 (en) | antihistamine syrups stable to sugar free storage | |
| EP4048230B1 (en) | Oral gliptin compositions and method for preparation thereof | |
| US5538989A (en) | Fenbendazole formulations | |
| CN101083984A (en) | Therapeutic compositions for intranasal administration of ketorolac | |
| EP1543826B1 (en) | Concentrated aqueous solution of ambroxol | |
| WO2012127497A1 (en) | Stable pharmaceutical compositions of ketorolac or salts thereof | |
| US20090325917A1 (en) | Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate | |
| US8853265B2 (en) | Oral composition to reduce cold symptoms and duration of same | |
| WO2000076507A1 (en) | Method for increasing the solubility of morphine and pharmaceutical compositions prepared therefrom | |
| CN115137699A (en) | Dexmedetomidine nasal spray with synergistic and antiseptic effects | |
| US5770618A (en) | Method for increasing the solubility of clemastine and pharmaceutical compositions prepared therefrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| AS | Assignment |
Owner name: SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED, A Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:BENJAMIN, ERIC;ANIK, SHABBIR;LIN, YA-YUN T.;REEL/FRAME:005370/0622 Effective date: 19900713 |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| AS | Assignment |
Owner name: DURA PHARMACEUTICALS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED;REEL/FRAME:008660/0178 Effective date: 19970507 |
|
| REFU | Refund |
Free format text: REFUND - PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: R184); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 12 |
|
| AS | Assignment |
Owner name: ELAN PHARMACEUTICALS, INC., CALIFORNIA Free format text: MERGER;ASSIGNOR:DURA PHARMACEUTICALS, INC.;REEL/FRAME:013835/0067 Effective date: 20011228 Owner name: QUADRANT TECHNOLOGIES LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ELAN PHARMACEUTICALS, INC.;REEL/FRAME:013835/0127 Effective date: 20030711 |